Cytiva Services Videos

1. The One Quality Metric That Actually Matters 3/12/2026

   This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection”, addresses the internal metrics that reveal a truly healthy quality culture, moving past standard marketing claims to zero in on deviation closure times, batch record cycle times, and CAPA effectiveness as reliable indicators of continuous improvement and operational maturity.

2. Navigating Private Equity Ownership In The CDMO Space 3/12/2026

   This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection” , addresses how to assess a CDMO's long-term financial stability under private equity ownership by outlining the exact questions sponsors should ask to uncover reinvestment plans and determine if leadership remains focused on core drug development operations.

3. What Great CDMO Selection Looks Like In 2026 3/12/2026

   This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection,” examines how experienced sponsors should redefine a “great” CDMO selection in 2026, moving beyond capacity and technical capability to focus on execution under uncertainty, the ability to manage change without contract disruption, right-first-time performance, and long-term business viability.

4. The "Bad News" Stress Test: How CDMOs Handle Escalation 3/12/2026

   This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection”, addresses how to test a CDMO's escalation pathways during due diligence by identifying key decision-makers and uncovering whether a prospective partner has a healthy, collaborative approach to problem-solving or defaults to finger-pointing when bad news arises.

5. The BioSecure Act And Unfiltered Supply Chain Realities 3/12/2026

   This segment of the Outsourced Pharma Live event, “The Unfiltered Truth About CDMO Selection”, addresses the critical necessity of gaining supplier-level visibility for raw materials and packaging amidst geopolitical risks, while exploring the unfiltered reality that technology transfers to established US-based suppliers take significant time and capital to execute properly.

6. Factors Which Impact mAb Process Scale-Up 9/7/2021

   Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

7. 5 Key Considerations When Choosing A Single-Use Bioreactor Platform 6/15/2017

   In deciding which single-use platform to choose, reliability and robustness are fundamental requirements. Beyond process performance, it is important to consider how control systems and automation come into play, how easy it is to implement the platform, and if the design is flexible enough to support varying production volumes.